Cargando…
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
Autores principales: | Michot, J.-M., Albiges, L., Chaput, N., Saada, V., Pommeret, F., Griscelli, F., Balleyguier, C., Besse, B., Marabelle, A., Netzer, F., Merad, M., Robert, C., Barlesi, F., Gachot, B., Stoclin, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136869/ https://www.ncbi.nlm.nih.gov/pubmed/32247642 http://dx.doi.org/10.1016/j.annonc.2020.03.300 |
Ejemplares similares
-
1688P Outcome of older cancer patients infected with COVID-19 at Gustave Roussy Cancer Center
por: Hauchecorne, M., et al.
Publicado: (2020) -
1639P Impact of COVID-19 on ongoing oncological and hematological treatment strategy
por: Bayle, A., et al.
Publicado: (2021) -
Severe COVID-19 in patients with hematological cancers presenting with viremia
por: Michot, J.M., et al.
Publicado: (2021) -
Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
por: Pommeret, F., et al.
Publicado: (2021) -
High levels of TNFα in patients with COVID-19 refractory to tocilizumab
por: Danlos, F.X., et al.
Publicado: (2021)